S426
Clinical - Gynaecological
ESTRO 2026
complete response rate (CRR) per RECIST v1.1, and safety per CTCAE v5.0.This trial is registered with ClinicalTrials.gov, number NCT04678791. Results: Totally 286 patients were enrolled between January 2021 and March 2022. 142 patients in the Nimo group (nimotuzumab combined with CCRT) and 144 in the CCRT group (CCRT alone). The baseline characteristics were balanced between the two groups. The 3- year PFS rate of the Nimo group was higher than that of CCRT group (87.2% vs. 77.4%, P=0.031). There was a significant difference in the risk ratio between the two groups (HR=0.53, 95% CI: 0.30-0.95, P=0.032). A total of 102 (71.83%) patients achieved complete response (CR) and 26 (18.31%) achieved partial response (PR) in the Nimo group, while 95 (65.97%) and 22 (15.28%) in the CCRT group, respectively. The ORR was 90.14% vs. 81.25% (P=0.032). The most common grade 1-2 AEs were anaemia (65.58%), leukopenia (49.64%), neutropenia (45.29%), nausea (42.75%), thrombocytopenia (38.04%), vomiting (27.54%), asthenia (22.10%), diarrhea (21.01%), lymphopenia (17.03%), hypokalaemia (16.30%) and hypoalbuminaemia (11.23%). Conclusion: Nimotuzumab combined with CCRT significantly improved the ORR in LACC patients with a good tolerance. CC3 study show that longer trend in PFS in the treatment of LACC patients. Keywords: Nimotuzumab; Cervical cancer; Phase 3
Jocelyn Z Mariano 2 , Jonalyn G Bagadiong 3 , Maurren R Bojador 1 , Stellar Marie R Cabrera 1 , Dan Joseph Manlupaz 4 , Warren R Bacorro 1,4 1 Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines. 2 Obstetrics & Gynecology, University of Santo Tomas Hospital, Manila, Philippines. 3 Obstetrics & Gynecology, East Avenue Medical Center, Quezon City, Philippines. 4 Radiation Oncology, East Avenue Medical Center, Quezon City, Philippines Purpose/Objective: To evaluate the safety, feasibility, and clinical effectiveness of moderate hypofractionated radiotherapy (HFRT) in patients with locally advanced or metastatic gynecologic malignancies, with a focus on symptom relief, treatment tolerability, and potential facilitation of subsequent systemic therapy in a multi-institutional, real-world setting. Material/Methods: We retrospectively analyzed 13 patients with locally advanced or metastatic gynecologic malignancies treated with 2.67 Gy × 15 fractions (40.05 Gy) HFRT between January 2024 and November 2025 across two institutions. Dose prescription and organ-at- risk constraints were guided by the HYACINCT trial, ensuring safe implementation of the hypofractionated regimen. Primary outcomes included symptom relief and safety, while secondary outcomes were treatment compliance and transition to systemic therapy. Radiologic reassessment was limited, hence symptom improvement served as the main efficacy measure. Results: All patients (100%) presented with pain; 6 (46%) also experienced bleeding, and another 6 (46%) had obstructive symptoms, such as pelvic pressure, constipation, or urinary difficulty. All patients received pelvic RT, of whom 8 (62%) received EFRT, 3 (23%) received inguinal RT, and 2 (15%) received RT to osseous or soft-tissue extensions. Five
Digital Poster 1497 A multi-institutional case series on
moderate hypofractionated radiotherapy for symptom relief in locally advanced and metastatic gynecologic cancers Patricia J Ong 1 , Vannesza Hendricke C Chua 1 , Leona Marie Francesca S Rebosa 1 , Bryce Matthew L Tan De Guzman 1 , Kelvin Ken L Yu 1 ,
Made with FlippingBook - Share PDF online